Enbrel Biosimilar Gets Green Light
Enbrel's new biosimilar recently got the green light it needed to treat several inflammatory health conditions.
Inflammatory Disease Rx Gets Green Light
The US Food and Drug Administration (FDA) has approved a new medication to treat multiple chronic inflammatory diseases.
Another Biosimilar Gets a Green Light
The US Food and Drug Administration (FDA) has approved another biosimilar. This one is meant to treat multiple conditions that affect the immune system.
Green Light for Biosimilar to Humira
The US Food and Drug Administration has approved its fourth biosimilar.
FDA Approves First Biosimilar Etanercept
The US Food and Drug Administration (FDA) has approved the first biosimilar etanercept.
Second Biosimilar Gets FDA Nod
The US Food and Drug Administration (FDA) has approved the second-ever biosimilar, and it's meant to treat multiple conditions that affect the immune system.
Anti-TNFs Not to Blame for Skin Infections in RA
Anti-TNF medications used to control arthritis symptoms have been linked to increased risks for skin infections. However, a recent study has shown that this may not necessarily be true.
Unequal Treatment for Psoriasis?
The type of medical care patients get depends on several factors. Some patients with psoriasis, or the arthritis that can accompany psoriasis, don't believe they get enough quality care.
Shingles Stay Quiet with RA Medicine
Returning outbreaks of shingles are more common in people with rheumatoid arthritis (RA). Until now, researchers were not sure how medicines for RA would affect the chance that the painful rash would return.
No Safety Surprises from Humira
Humira (adalimumab) is a medication used to treat a variety of diseases. As the medication is being prescribed to more and more patients, researchers wanted to see if there were any side effects they didn't know about before.